nach oben

Erschienen in:

01.02.2013 | Original Article

In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts

verfasst von: Jianxia Guo, Dana M. Clausen, Jan H. Beumer, Robert A. Parise, Merrill J. Egorin, Karla Bravo-Altamirano, Peter Wipf, Elizabeth R. Sharlow, Qiming Jane Wang, Julie L. Eiseman

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Protein kinase D (PKD) mediates diverse biological responses including cell growth and survival. Therefore, PKD inhibitors may have therapeutic potential. We evaluated the in vitro cytotoxicity of two PKD inhibitors, kb-NB142-70 and its methoxy analogue, kb-NB165-09, and examined their in vivo efficacy and pharmacokinetics.

Methods

The in vitro cytotoxicities of kb-NB142-70 and kb-NB165-09 were evaluated by MTT assay against PC-3, androgen-independent prostate cancer cells, and CFPAC-1 and PANC-1, pancreatic cancer cells. Efficacy studies were conducted in mice bearing either PC-3 or CPFAC-1 xenografts. Tumor-bearing mice were euthanized between 5 and 1,440 min after iv dosing, and plasma and tissue concentrations were measured by HPLC–UV. Metabolites were characterized by LC–MS/MS.

Results

kb-NB142-70 and kb-NB165-09 inhibited cellular growth in the low–mid μM range. The compounds were inactive when administered to tumor-bearing mice. In mice treated with kb-NB142-70, the plasma C _max was 36.9 nmol/mL, and the PC-3 tumor C _max was 11.8 nmol/g. In mice dosed with kb-NB165-09, the plasma C _max was 61.9 nmol/mL, while the PANC-1 tumor C _max was 8.0 nmol/g. The plasma half-lives of kb-NB142-70 and kb-NB165-09 were 6 and 14 min, respectively. Both compounds underwent oxidation and glucuronidation.

Conclusions

kb-NB142-70 and kb-NB165-09 were rapidly metabolized, and concentrations in tumor were lower than those required for in vitro cytotoxicity. Replacement of the phenolic hydroxyl group with a methoxy group increased the plasma half-life of kb-NB165-09 2.3-fold over that of kb-NB142-70. Rapid metabolism in mice suggests that next-generation compounds will require further structural modifications to increase potency and/or metabolic stability.

Nur mit Berechtigung zugänglich

Rennecke J, Rehberger PA, Fürstenberger G, Johannes FJ, Stöhr M, Marks F, Richter KH (1999) Protein-kinase-Cmu expression correlates with enhanced keratinocyte proliferation in normal and neoplastic mouse epidermis and in cell culture. Int J Cancer 80:98–103PubMedCrossRef

Zhukova E, Sinnett-Smith J, Rozengurt E (2001) Protein kinase D potentiates DNA synthesis and cell proliferation induced by bombesin, vasopressin, or phorbol esters in swiss 3T3 cells. J Biol Chem 276:40298–40305PubMed

Johannes FJ, Horn J, Link G, Haas E, Siemienski K, Wajant H, Pfizenmaier K (1998) Protein kinase Cmu downregulation of tumor-necrosis-factor-induced apoptosis correlates with enhanced expression of nuclear-factor-kappaB-dependent protective genes. Eur J Biochem 257:47–54PubMedCrossRef

Endo K, Oki E, Biedermann V, Kojima H, Yoshida K, Johannes FJ, Kufe D, Datta R (2000) Proteolytic cleavage and activation of protein kinase C [micro] by caspase-3 in the apoptotic response of cells to 1-beta-d-arabinofuranosylcytosine and other genotoxic agents. J Biol Chem 275:18476–18481PubMedCrossRef

Brändlin I, Hübner S, Eiseler T, Martinez-Moya M, Horschinek A, Hausser A, Link G, Rupp S, Storz P, Pfizenmaier K, Johannes FJ (2002) Protein kinase C (PKC)eta-mediated PKC mu activation modulates ERK and JNK signal pathways. J Biol Chem 277:6490–6496PubMedCrossRef

Rey O, Young SH, Cantrell D, Rozengurt E (2001) Rapid protein kinase D translocation in response to G protein-coupled receptor activation. J Biol Chem 276:32616–32626PubMedCrossRef

Paolucci L, Rozengurt E (1999) Protein kinase D in small cell lung cancer cells: rapid activation through protein kinase C. Cancer Res 59:572–577PubMed

Sidorenko SP, Law CL, Klaus SJ, Chandran KA, Takata M, Kurosaki T, Clark EA (1996) Protein kinase C mu (PKC mu) associates with the B cell antigen receptor complex and regulates lymphocyte signaling. Immunity 5:353–363PubMedCrossRef

Rozengurt E, Sinnett-Smith J, Van Lint J, Valverde AM (1995) Protein kinase D: a novel target for diacylglycerol and phorbol esters. Mutat Res 326:545–551

10.

Haworth RS, Sinnett-Smith J, Rozengurt E, Avkiran M (1999) Protein kinase D inhibits plasma membrane Na⁺/H⁺ exchanger activity. Am J Physiol 277:C1202–C1209PubMed

11.

Rykx A, Kimpe LD, Mikhalap S, Vantus T, Seufferlein T, Vandenheede JR, Lint JV (2003) Protein kinase D: a family affair. FEBS Lett 546:81–86PubMedCrossRef

12.

Eiseler T, Döppler H, Yan IK, Goodison S, Storz P (2009) Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res 11(1):R13PubMedCrossRef

13.

Papazyan R, Rozengurt E, Rey O (2006) The C-terminal tail of protein kinase D2 and protein kinase D3 regulates their intracellular distribution. Biochem Biophys Res Commun 342(3):685–689PubMedCrossRef

14.

Lu G, Chen J, Espinoza LA, Garfield S, Toshiyuki S, Akiko H, Huppler A, Wang QJ (2007) Protein kinase D 3 is localized in vesicular structures and interacts with vesicle-associated membrane protein 2. Cell Signal 19(4):867–879PubMedCrossRef

15.

Marklund U, Lightfoot K, Cantrell D (2003) Intracellular location and cell context-dependent function of protein kinase D. Immunity 19(4):491–501PubMedCrossRef

16.

Hassan S, Biswas MH, Zhang C, Du C, Balaji KC (2009) Heat shock protein 27 mediates repression of androgen receptor function by protein kinase D1 in prostate cancer cells. Oncogene 28(49):4386–4396PubMedCrossRef

17.

Matthews SA, Navarro MN, Sinclair LV, Emslie E, Feijoo-Carnero C, Cantrell DA (2010) Unique functions for protein kinase D1 and protein kinase D2 in mammalian cells. Biochem J 432(1):153–163PubMedCrossRef

18.

American Cancer Society: Cancer Facts and Figures 2009. Atlanta, Ga: American Cancer Society, 2009. Also available online. Last accessed May 7, 2009

19.

Amadesi S, Grant AD, Cottrell GS, Vaksman N, Poole DP, Rozengurt E, Bunnett NW (2009) Protein kinase D isoforms are expressed in rat and mouse primary sensory neurons and are activated by agonists of protease-activated receptor 2. J Comp Neurol 516(2):141–156PubMedCrossRef

20.

Chen LA, Li J, Silva SR, Jackson LN, Zhou Y, Watanabe H, Ives KL, Hellmich MR, Evers BM (2009) PKD3 is the predominant protein kinase D isoform in mouse exocrine pancreas and promotes hormone-induced amylase secretion. J Biol Chem 284(4):2459–2471PubMedCrossRef

21.

Rey O, Yuan J, Rozengurt E (2003) Intracellular redistribution of protein kinase D2 in response to G-protein-coupled receptor agonists. Biochem Biophys Res Commun 302:817–824PubMedCrossRef

22.

Rey O, Yuan J, Young SH, Rozengurt E (2003) Protein kinase C nu/protein kinase D3 nuclear localization, catalytic activation, and intracellular redistribution in response to G protein-coupled receptor agonists. J Biol Chem 278:23773–23785PubMedCrossRef

23.

Yuan J, Rozengurt E (2008) PKD, PKD2, and p38 MAPK mediate Hsp27 serine-82 phosphorylation induced by neurotensin in pancreatic cancer PANC-1 cells. J Cell Biochem 103(2):648–662PubMedCrossRef

24.

Seufferlein T (2002) Novel protein kinases in pancreatic cell growth and cancer. Int J Gastrointest Cancer 31(1–3):15–21PubMedCrossRef

25.

Guha S, Rey O, Rozengurt E (2002) Neurotension induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res 62:1632–1640PubMed

26.

Du C, Jaggi M, Zhang C, Balaji KC (2009) Protein kinase D1-mediated phosphorylation and subcellular localization of beta-catenin. Cancer Res 69(3):1117–1124PubMedCrossRef

27.

Mak P, Jaggi M, Syed V, Chauhan SC, Hassan S, Biswas H, Balaji KC (2008) Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells. Biochem Biophys Res Commun 373(4):618–623PubMedCrossRef

28.

Chen J, Deng F, Singh SV, Wang QJ (2008) Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res 68(10):3844–3853PubMedCrossRef

29.

Sturany S, Lint JV, Gilchrist A, Vandenheede JR, Adler G, Seufferlein T (2002) Mechanism of activation of protein kinase D2(PKD2) by the CCKB/gastrin receptor. J Biol Chem 277:29431–29436PubMedCrossRef

30.

Jaggi M, Rao PS, Smith DJ, Wheelock MJ, Johnson KR, Hemstreet GP, Balaji KC (2005) E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. Cancer Res 65:483–492PubMed

31.

Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Foxton C, Boakes A, Farooq M, Maru D, Diagaradjane P, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, Guha S (2010) A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther 9:1136–1145PubMedCrossRef

32.

Stewart JR, Christman KL, O’Brian CA (2000) Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem Pharmacol 60(9):1355–1359PubMedCrossRef

33.

Sharlow ER, Giridhar KV, LaValle CR, Chen J, Leimgruber S, Barrett R, Bravo-Altamirano K, Wipf P, Lazo JS, Wang QJ (2008) Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J Biol Chem 283(48):33516–33526PubMedCrossRef

34.

LaValle CR, Bravo-Altamirano K, Giridhar KV, Chen J, Sharlow E, Lazo JS, Wipf P, Wang QJ (2010) Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol 10:5PubMedCrossRef

35.

Bravo-Altamirano K, George KM, Frantz MC, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P (2011) Synthesis and structure-activity relationships of benzothienothiazepinone inhibitors of protein kinase D. ACS Med Chem Lett 2(2):154–159PubMedCrossRef

36.

George KM, Frantz M-CL, Bravo-Altamirano K, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P (2011) Design, synthesis, and biological evaluation of PKD inhibitors. Pharmaceutics 3(2):186–228PubMedCrossRef

37.

D’Argenio DZ, Schumitzky A. ADAPT, Biomedical Simulation Resource, USC. bmsr.usc.edu/Software/ADAPT/ADAPT.html

38.

Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 6:79–98PubMedCrossRef

39.

Rocci ML, Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 16:203–216PubMedCrossRef

40.

Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–484PubMed

41.

LaValle CR, George KM, Sharlow ER, Lazo JS, Wipf P, Wang QJ (2010) Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta 1806:183–192PubMed

42.

Ochi N, Tanasanvimon S, Matsuo Y, Tong Z, Sung B, Aggarwal BB, Sinnett-Smith J, Rozengurt E, Guha S (2011) Protein kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells. J Cell Physiol 226:1074–1081PubMedCrossRef

43.

Ristich VL, Bowman PH, Dodd ME, Bollag WB (2006) Protein kinase D distribution in normal human epidermis, basal cell carcinoma and psoriasis. Br J Dermatol 154:586–593PubMedCrossRef

44.

Kisfalvi K, Hurd C, Guha S, Rozengurt E (2010) Induced overexpression of protein kinase D1 stimulates mitogenic signaling in human pancreatic carcinoma PANC-1 cells. J Cell Physiol 223:309–316PubMed

45.

Chen J, Giridhar KV, Zhang L, Xu S, Wang QJ (2011) A protein kinase C/protein kinase D pathway protects LNCaP prostate cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF-{kappa}B activities. Carcinogenesis 32:1198–1206PubMedCrossRef

Titel: In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts
verfasst von: Jianxia Guo
Dana M. Clausen
Jan H. Beumer
Robert A. Parise
Merrill J. Egorin
Karla Bravo-Altamirano
Peter Wipf
Elizabeth R. Sharlow
Qiming Jane Wang
Julie L. Eiseman
Publikationsdatum: 01.02.2013
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2013
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-2010-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis

A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer

Erratum to: Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation

Combination of three cytotoxic agents in small-cell lung cancer

Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours

Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie